莱达西贝普(Lerodalcibep) - 药物靶点：PCSK9_在研适应症：动脉粥样硬化，杂合子家族性高胆固醇血症，纯合子家族性高胆固醇血症_专利_临床

概要

基本信息

药物类型

融合蛋白

别名

HST101、LIB-003、LIB003

靶点

PCSK9

作用方式

抑制剂

作用机制

PCSK9抑制剂(前蛋白转化酶枯草杆菌蛋白酶Kexin-9抑制剂)

治疗领域

心血管疾病遗传病与畸形内分泌与代谢疾病+ [1]

在研适应症

动脉粥样硬化杂合子家族性高胆固醇血症纯合子家族性高胆固醇血症+ [10]

非在研适应症-

原研机构

LIB Therapeutics LLC

在研机构

LIB Therapeutics LLC海森生物医药有限公司

LIB Therapeutics

非在研机构-

权益机构

海森生物医药有限公司

LIB Therapeutics

最高研发阶段申请上市

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 454015655

来源: *****

关联

16

项与莱达西贝普相关的临床试验

NCT07102511

/ Not yet recruiting临床3期

Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, With Heterozygous Familial Hypercholesterolemia on Stable Diet and Oral Lipid-Lowering Therapy

The goal of this clinical trial is to assess the LDL-Cholesterol reductions at Week 12 and Week 24 with monthly dosing of lerodalcibep (Lerochol) 300 mg administered subcutaneously by auto-injector (AI)/pre-filled pen (PFP) compared to placebo (dummy), in male and female pediatric patients 6 to 17 years of age, with inherited high cholesterol (HeFH) on a stable diet and maximally tolerated oral LDL C lowering drug therapy such as statins.
The main question[s] it aims to answer are:
How effective is Lerochol in reducing LDL cholesterol? How well is it tolerated and are there any safety concerns? Researchers will compare Lerochol to placebo (inert or dummy injection solution).
Participants will visit the clinic every month for months and be asked to fast overnight, but allowed to drink water, before clinic visits. Undergo physical exams, height and weight measurements, answer questions, have blood drawn from a vein in their arm, have blood pressure measurements, EKC heart tests, and receive monthly injections lasting about 5 seconds in their arms or abdomen with an autoinjector.

开始日期2025-09-01

申办/合作机构

LIB Therapeutics LLC

NCT06568471

/ Recruiting临床3期

A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

This randomized study is to assess LDL-C reductions at Week 12 with monthly (Q4W [≤31 days]) dosing of HST101 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with atherosclerotic cardiovascular disease (ASCVD) or very-high/high risk for ASCVD including Heterozygous familial hypercholesterolemia (HeFH) on a stable diet and oral LDL-C lowering drug therapy, followed by 36-week open-label treatment with subsequent 4-week follow-up for total 52-week long-term safety and efficacy evaluation.

开始日期2024-11-16

申办/合作机构

海森生物医药有限公司

ChiCTR2400089193

/ Not yet recruiting临床3期IIT

A randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of HST101 in Chinese patients with hypercholesterolemia

开始日期2024-09-30

申办/合作机构

北京大学第一医院

[+2]

100 项与莱达西贝普相关的临床结果

登录后查看更多信息

100 项与莱达西贝普相关的转化医学

登录后查看更多信息

100 项与莱达西贝普相关的专利（医药）

登录后查看更多信息

3

项与莱达西贝普相关的文献（医药）

2025-12-01·Current Atherosclerosis Reports

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions

Review

作者: Khoja, Adeel ; Inam, Maha ; Murthy, Nikitha ; Epstein, Elizabeth ; Virani, Salim S ; Vaughan, Elizabeth ; Sheikh, Sana ; Mehta, Sandeep ; Minhas, Abdul Mannan Khan ; Slipczuk, Leandro ; Junaid, Vashma ; Chai, Zohar ; Hinkamp, Colin ; Hermel, Melody

PURPOSE OF REVIEW:

Focused review highlighting ten select studies presented at the 2024 American Heart Association (AHA) Scientific Sessions.

RECENT FINDING:

Included studies assessed effects of intensive blood pressure control in patients with type 2 diabetes (BPROAD); decision support system for physicians to optimize early lipid lowering therapies after acute coronary syndrome (ZODIAC); efficacy and safety of zerlasiran, a short interfering RNA targeting lipoprotein(a) (ALPACAR); efficacy and safety of muvalaplin an oral disrupter of the assembly of lipoprotein(a) particles (KRAKEN); safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia (BROOKLYN); efficacy and safety of lerodalcibep, a third generation PCSK9 inhibitor in heterozygous familial hypercholesterolemia subjects (LIBerate-HeFH_OLE); personalized app-based coaching to improve physical activity in patients with HFpEF compared to standard care (MyoMobile); semaglutide to improve cardiovascular outcomes in patients with a history of coronary artery bypass surgery and overweight or obesity (the SELECT trial); efficacy and safety of plozasiran in adults with genetically or clinically defined familial chylomicronemia syndrome at high risk of acute pancreatitis (PALISADE); and transcriptomic signatures and predictors of evolocumab added to maximum statin therapy based on intra-coronary plaque characteristics (YELLOW III). Research presented at the 2024 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.

2025-08-01·CURRENT OPINION IN LIPIDOLOGY

Safety and effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition: an updated review

Review

作者: Pamporis, Konstantinos ; Tsiachris, Dimitrios ; Karakasis, Paschalis

Purpose of review:

To summarize the recent literature on the effectiveness and safety of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in reducing low-density lipoprotein cholesterol (LDL-C) and mitigating atherosclerotic cardiovascular disease (ASCVD) risk.

Recent findings:

PCSK9i demonstrated considerable benefits in patients with acute myocardial infarction (AMI). Within an intensive lipid-lowering strategy (“strike early-strike strong”), these agents were associated with improved outcomes, primarily through LDL-C reductions and atheromatous plaque regression and stabilization, particularly in multivessel disease. In heterozygous familial hypercholesterolemia, significant LDL-C reductions were noted for alirocumab (−43.3%) and lerodalcibep (−58.6%), while in homozygous hypercholesterolemia, lerodalcibep (−4.9%) and inclisiran (−1.68%) were ineffective, with evolocumab demonstrating a superior −10.3% LDL-C reduction. PCSK9i exhibit a favorable safety profile and high adherence rates; nevertheless, concerns have been raised in patients with respiratory comorbidities and during pregnancy. Additionally, challenges like high costs and complex authorization procedures limit their widespread implementation. Clinicians should also be mindful of the potential discontinuation of concurrent lipid-lowering therapies following PCSK9i initiation.

Summary:

PCSK9i remain integral in ASCVD risk reduction, given their potent LDL-C-lowering effects, all while maintaining a favorable safety profile. The greatest benefits are observed in patients with AMI, particularly in multivessel disease. Despite high adherence, broader utilization is hindered by persistent challenges, including costs and complex authorization processes.

Cardiovascular diabetology

The translational potential of miR-26 in atherosclerosis and development of agents for its target genes ACC1/2, COL1A1, CPT1A, FBP1, DGAT2, and SMAD7

Review

作者: Wang, Yanhong ; Zhang, Shuangshuang ; Zhu, Meng ; Hu, Weichao ; Wang, Jie ; Hu, Jianxia ; Wu, Xiaolin ; Liu, Xiaolei ; Xing, Dongming ; Chen, Wujun ; Wu, Jianfeng ; Wang, Chao ; Shao, Yingchun ; Guo, Zhu ; Hao, Minglu ; Zhang, Miao ; Wu, Yudong

Abstract:

Atherosclerosis is one of the leading causes of death worldwide. miR-26 is a potential biomarker of atherosclerosis. Standardized diagnostic tests for miR-26 (MIR26-DX) have been developed, but the fastest progress has been in predicting the efficacy of IFN-α therapy for hepatocellular carcinoma (HCC, phase 3). MiR-26 slows atherosclerosis development by suppressing ACC1/2, ACLY, ACSL3/4, ALDH3A2, ALPL, BMP2, CD36, COL1A1, CPT1A, CTGF, DGAT2, EHHADH, FAS, FBP1, GATA4, GSK3β, G6PC, Gys2, HMGA1, HMGB1, LDLR, LIPC, IL-1β, IL-6, JAG2, KCNJ2, MALT1, β-MHC, NF-κB, PCK1, PLCβ1, PYGL, RUNX2, SCD1, SMAD1/4/5/7, SREBF1, TAB3, TAK1, TCF7L2, and TNF-α expression. Many agents targeting these genes, such as the ACC1/2 inhibitors GS-0976, PF-05221304, and MK-4074; the DGAT2 inhibitors IONIS-DGAT2Rx, PF-06427878, PF-0685571, and PF-07202954; the COL1A1 inhibitor HT-100; the stimulants 68Ga-CBP8 and RCT-01; the CPT1A inhibitors etomoxir, perhexiline, and teglicar; the FBP1 inhibitors CS-917 and MB07803; and the SMAD7 inhibitor mongersen, have been investigated in clinical trials. Interestingly, miR-26 better reduced intima-media thickness (IMT) than PCSK9 or CT-1 knockout. Many PCSK9 inhibitors, including alirocumab, evolocumab, inclisiran, AZD8233, Civi-007, MK-0616, and LIB003, have been investigated in clinical trials. Recombinant CT-1 was also investigated in clinical trials. Therefore, miR-26 is a promising target for agent development. miR-26 promotes foam cell formation by reducing ABCA1 and ARL4C expression. Multiple materials can be used to deliver miR-26, but it is unclear which material is most suitable for mass production and clinical applications. This review focuses on the potential use of miR-26 in treating atherosclerosis to support the development of agents targeting it.

51

项与莱达西贝普相关的新闻（医药）

2025-10-03

·Pharmaceutical Technology

Amgen’s Phase III data supports FDA label expansion of Repatha

Takeda’s (Japan) Zejula (niraparib) was one of among six innovative anti-cancer medicines across 20 indications that were considered in this study. Credit: Melnikov Dmitriy / Shutterstock. Amgen is hopeful that Phase III data will cement the validity of its recently approved widened label for cholesterol-lowering drug Repatha (evolocumab). In August 2025, the US Food and Drug Administration (FDA) approved the use of Repatha in adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C). Now, the VESALIUS-CV trial (NCT03872401) has proved its long-term efficacy in these patients after meeting both its primary endpoints, proving that Repatha can significantly reduce the risk of MACE in patients without a prior history of heart attack or stroke. The primary endpoints were time to first occurrence of a composite of coronary heart disease (CHD) death, heart attack or ischemic stroke, and time to first occurrence of a composite of CHD death, heart attack, ischemic stroke or any ischemia-driven arterial revascularisation. The trial enrolled more than 12,000 high-risk patients who were followed for 4.5 years. Of those enrolled, approximately 85% were maintained on a high-intensity or moderate LDL-C reducing therapy. Amgen R&D executive vice-president Dr Jay Bradner said: “The benefit across endpoints and established safety profile underscore Repatha’s role as a cornerstone therapy in comprehensive lipid management. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence “Repatha is known as a highly effective LDL-C-lowering treatment and is now the first and only PCSK9 inhibitor shown to reduce cardiovascular events in high-risk adults without prior heart attack or stroke. These additional data demonstrate that Repatha has the potential to reach tens of millions more patients earlier in their journey, before a life-altering event occurs.” Amgen has not yet released data from the trial; however, this is set to be presented at the American Heart Association Scientific Sessions on 8 November. Repatha was first approved in the US for adults with high cholesterol who require further LDL-C reduction on 27 August 2015. This came after European approval, making it the first PCSK9 inhibitor to receive regulatory clearance worldwide. Its long market presence means it is coming close to the end of its patent-protected period, due to end in 2030, opening up an opportunity for biosimilars. GlobalData predicts this will dent Amgen’s market dominance, with peak sales for the drug reaching $3.87bn in 2029 before slowly dropping, with a 2031 sales forecast of $3.32bn. GlobalData is the parent company of Clinical Trials Arena . Repatha’s main market competition comes from Praluent (alirocumab), a PCSK9 inhibitor developed by Regeneron and Sanofi, which gained US approval before Repatha, but EU approval came later. Praluent sales are set to reach $880m in 2031, according to GlobalData. After Praulent’s approval, Regeneron and Sanofi, and Amgen were embroiled in a patent dispute over the two therapies, with Amgen emerging victorious . Amgen also faces competition from Novartis’ Leqvio (inclisiran), a long-acting small-interfering RNA (siRNA) that degrades PCSK9. GlobalData predicts sales will rise sharply, from $754m in 2024 to $3.98bn in 2031. A number of LDL-C-lowering drugs have also recently shown promise, including LIB Therapeutics’ lerodalcibep, AstraZeneca’s AZD0780 and NewAmsterdam Pharma’s obicetrapib. GlobalData predicts the total dyslipidemia (high cholesterol) market will reach $15.53bn across seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) by 2032. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

上市批准临床3期临床结果AHA会议

2025-09-05

·药通社

恒瑞年轻副总，辞职赴任CEO！

9月2日，海森生物发布消息称，刘文军担任公司首席执行官(CEO)，其将全面执掌海森生物战略规划与运营管理体系。海森生物CEO刘文军公开资料显示，刘文军乃是恒瑞前高管，其在恒瑞任职期间为公司创造了诸多亮眼的成绩，包括开拓降尿酸药非布司他院外市场、负责恒瑞用于成人2型糖尿病患者血糖控制的原研重点产品“恒格列净”的市场开发、负责恒瑞组织架构调整后的代谢疼痛产品线等。 2024年，年仅35岁的刘文军被任命为综合产品事业部副总经理，依旧主管代谢疼痛产品线，但仅任新职位一年，其于今年8月突然宣布辞职，并且去向未知。如今，刘文军的新“东家”有了着落。海森生物网站显示，集研发、生产和商业推广，覆盖全产业链的海森生物是一家创新型生物医药企业，成立于2020年，由亚洲一家专注于医疗健康行业的资产管理公司——康桥资本、合肥产投集团与合肥市肥东县共同投资组建。2023年4月，海森生物获得来自康桥资本和阿布扎比主权财富基金穆巴达拉投资公司等机构新一轮的融资，用于未来的收购和创新产品管线的业务发展。目前，公司的业务覆盖中国大陆、瑞士及泛亚太8个国家和地区，产品聚焦于慢性病和急重症治疗领域。 ↓ 扫码加入药通社交流群 ↓ 近年来，该公司为丰富其产品管线，对外收购、合作动作频频。例如，2020年12月，海森生物以3.2亿美元收购了武田制药在中国区心血管和代谢领域处方药业务，将后者包括沙坦类降压药美阿沙坦钾片(易达比)、坎地沙坦酯片(必洛斯)、伏格列波糖片(倍欣)、盐酸吡格列酮片(艾可拓)以及用于急重症的盐酸乌拉地尔注射液(亚宁定)等产品收入囊中。 2023年5月，海森生物子公司宣布与罗氏达成合作，将独家拥有注射用头孢曲松钠(罗氏芬)在中国大陆的专有权。同年9月，海森生物和LIB Therapeutics Inc.联合宣布就海森生物在大中华区(包括中国大陆和港澳台地区)开发及商业化Lerodalcibep达成许可协议。Lerodalcibep融合蛋白是由LIB Therapeutics开发的第三代长效PCSK9抑制剂，每月一针皮下注射，对解决当前临床降脂治疗中未被满足的需求具有潜力，有望助力更多高脂血症患者实现血脂控制达标，目前正处于III期临床开发阶段。 2024年6月28日，海森生物又宣布正式完成对韩国生物制药企业Celltrion旗下14种品牌产品在亚太多个国家和地区商业权益的收购，并拥有这些产品在包括韩国*、新加坡、泰国、澳大利亚、中国香港等8个国家及地区的药品上市许可持有人(MAH)权益。随着刘文军的加入，业内认为这是海森生物强化领导团队、加速业务拓展的重要信号。未来，刘文军能否助力海森生物再创佳绩，值得持续关注。 ↓⭐关注药通社，洞见行业趋势↓ 投稿/企业合作/内容沟通：药通社总编—华籍美人（Ww_150525） *添加请注明备注及来意

2025-08-25

·海森生物

海森生物I类创新药HST101中国3期临床试验顶线结果公布，降脂疗效显著！

2025年8月25日，海森生物医药有限公司（以下简称“海森生物”）宣布第三代新型PCSK9抑制剂Lerodalcibep（以下称为HST101）中国3期临床试验取得了又一重大里程碑进展！该研究为针对中国高胆固醇血症包括杂合子型家族性高胆固醇血症(HeFH)患者的关键注册性研究，已完成12周随机、双盲、安慰剂对照治疗期的顶线数据分析。结果显示HST101 降低低密度脂蛋白胆固醇（LDL-C）的疗效显著，有望成为当下火热爆点之一的PCSK9抑制剂家族的又一位实力派“新秀”。 HST101中国3期临床试验12周随机双盲期顶线数据结果表明： 1 HST101 300 mg 每月一次皮下注射给药后，经安慰剂校正后，第12周HST101组受试者的血清LDL-C水平较基线降低65.88%； 2 经安慰剂校正后，HST101组第10周和第12周的平均LDL-C浓度较基线降低67.04%； 3 本次顶线数据结果不仅达到了主要疗效终点，而且安全耐受性良好。霍勇北京大学第一医院心内科首席专家近几十年来，中国人群血脂异常患病率明显增加，以高胆固醇血症的增加最为明显。大量研究证实低密度脂蛋白胆固醇（LDL-C）是动脉粥样硬化性心血管疾病(ASCVD)最重要且容易改变的致病性危险因素之一，已被国内外血脂管理指南确定为防治ASCVD的首要干预靶点，但国内患者的LDL-C达标率仍很不理想。该3期研究的顶线结果证实了HST101在中国高胆固醇血症患者中显著降低LDL-C水平，达到了主要疗效终点，预示着HST101有望顺利获批上市，从而为医生或患者提供另一种PCSK9抑制剂治疗新选择，而且其每月一次皮下注射给药、以及室温下（25℃以下）可稳定保存长达6个月的优势将更方便患者使用，进一步提高患者的用药依从性。刘蒙海森生物医药有限公司副总裁、医学部负责人很欣喜的看到HST101在国内3期临床试验中取得这么积极的顶线成果，有望为医患提供更具临床价值的治疗新选择。海森生物研发团队正在进一步对数据进行全面深入分析，以便能早日将完整的临床研究报告递交上市申请，助力更多高脂血症患者人群实现LDL-C达标。新型第三代PCSK9抑制剂Lerodalcibep（HST101）是海森生物携手LIB Therapeutics引入的首个在研创新药。HST101国内3期临床试验取得的积极研究结果，不仅标志着海森生物在慢性病领域临床研发取得了里程碑式的进展，也充分显示了公司研发能力以及惠及更多患者的长期承诺。未来，海森生物将继续与临床专家紧密合作，携手合作伙伴全力推进HST101早日上市，为广大慢性病患者提供更加优质的产品和解决方案。注：本文涉及研究中的药品尚未在中国获批，海森生物不推荐任何未被批准的药品使用。关于HST101国内3期临床试验（HST101-301） HST101国内3期临床试验（HST101-301）共纳入213例中国患有ASCVD或ASCVD高危成人患者（包含HeFH）患者，12周随机双盲治疗期内，以2：1的比例随机分配至HST101组或安慰剂组，分别接受HST101 300 mg或安慰剂Q4W （≤31天）皮下注射给药治疗。所有受试者在入组时均已接受稳定的中等或高强度他汀类药物（联合或不联合依折麦布/海博麦布）治疗，但LDL-C水平仍未达标。共同的主要有效性终点是与安慰剂相比，第12周LDL-C水平较基线的百分比变化；第10周和第12周平均LDL-C水平较基线的百分比变化。目前所有受试者均已完成12周双盲治疗期，将进入为期36周的开放标签治疗期接受HST101 300 mg Q4W给药，之后是4周随访期，研究时长共52周。关于Lerodalcibep (HST101) Lerodalcibep是一种基于Adnectin设计的分子量较小的融合蛋白，是新型第三代PCSK9抑制剂，已被开发为一种每月一次、注射容积小、每次仅需一针皮下注射、居家或旅行时方便携带、无需冷藏的更方便患者使用的药物。这些特点使Lerodalcibep有望成为已获批准的 PCSK9 抑制剂中独特的替代品。Lerodalcibep的抗PCSK9结合域是一个分子量仅为 10.4kDa 称为adnectin的多肽，能与人类的PCSK９高度亲和，其亲和力达到亚纳摩尔级，并且与人血清白蛋白融合，以延长血浆半衰期。在FDA受理Lerodalcibep的生物制剂许可证申请（BLA）后，LIB已于2025年第二季度向欧洲药品管理局（EMA）提交上市许可申请。关于 LIB Therapeutics Inc. LIB Therapeutics是一家私人控股的后期生物制药公司，致力于将Lerodalcibep提供给数百万心血管疾病患者和全球3,000万家族性高胆固醇血症（FH）患者。尽管他汀类药物和其他降脂药物已达到最大耐受量，但这些患者仍需要额外大幅降低低密度脂蛋白胆固醇（LDL-C），以达到 LDL-C 目标。关于海森生物医药有限公司海森生物医药有限公司（简称：海森生物）是一家成立于2020年的创新型生物医药企业，业务聚焦于慢性病和急重症领域，致力于成为生物医药卓越商业平台和创新引领者。海森生物始终秉持以患者为中心的价值观，通过可持续的商业化造血能力，加速优质产品价值转化，提供创新的治疗方案，守护患者健康，共创社会健康价值。往期精选海森生物美国合作伙伴LIB Therapeutics宣布其生物制品Lerodalcibep上市申请获FDA受理海森生物合作伙伴LIB宣布向FDA递交Lerodalcibep用于治疗成人低密度脂蛋白胆固醇升高的生物制品许可申请海森生物 I 类创新药HST101 III期临床试验完成首例受试者入组给药！欢迎分享，喜欢也请点个“赞”和“在看”吧

临床3期临床结果临床成功

100 项与莱达西贝普相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
动脉粥样硬化	申请上市	美国	LIB Therapeutics LLC	2024-12-16
杂合子家族性高胆固醇血症	申请上市	美国	LIB Therapeutics LLC	2024-12-16
纯合子家族性高胆固醇血症	申请上市	美国	LIB Therapeutics LLC	2024-12-16
原发性高脂血症	申请上市	美国	LIB Therapeutics LLC	2024-12-16
原发性高胆固醇血症	临床3期	中国	海森生物医药有限公司	2024-11-16
动脉粥样硬化性闭塞性疾病	临床3期	法国	LIB Therapeutics LLC	2022-06-20
动脉粥样硬化性闭塞性疾病	临床3期	德国	LIB Therapeutics LLC	2022-06-20
动脉粥样硬化性闭塞性疾病	临床3期	挪威	LIB Therapeutics LLC	2022-06-20
动脉粥样硬化性闭塞性疾病	临床3期	西班牙	LIB Therapeutics LLC	2022-06-20
动脉粥样硬化性闭塞性疾病	临床3期	英国	LIB Therapeutics LLC	2022-06-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


CTR20242095 (NEWS) 人工标引	临床3期	高胆固醇血症	213	HST101	範網簾廠繭憲獵夢醖遞(築窪鏇醖衊襯襯顧選構) = HST101 300 mg 每月一次皮下注射给药后，达到了第12周血清 LDL-C降低的主要终点艱齋襯餘壓範範艱衊觸 (衊艱窪製獵艱鏇築醖願 ) 达到更多	积极	2025-08-25
				Placebo
NCT04034485 (LIBerate-HoFH, Pubmed) 人工标引	临床3期	纯合子家族性高胆固醇血症	66	Lerodalcibep 300 mg	窪夢選艱夢鬱醖築鹽顧(廠淵窪衊鑰製廠範鬱簾) = 積淵網襯鹹窪簾製鹹醖糧獵糧範廠繭範齋範願 (糧顧製艱觸鑰鬱壓顧艱, 3.5) 更多	不佳	2025-03-01
				EvolocumabEvolocumab 420 mg	窪夢選艱夢鬱醖築鹽顧(廠淵窪衊鑰製廠範鬱簾) = 憲窪鑰積築網遞鏇範遞糧獵糧範廠繭範齋範願 (糧顧製艱觸鑰鬱壓顧艱, 3.5) 更多
NCT04798430 (LIBerate-OLE, Biospace) 人工标引	临床3期	心血管疾病 \| 纯合子家族性高胆固醇血症 \| 杂合子家族性高胆固醇血症 ... 更多	1,468	Lerodalcibep	醖膚糧壓積襯鏇糧積蓋(獵淵範窪鬱簾製衊襯顧) = 願鹹醖顧鹹網齋遞蓋憲廠壓積糧衊蓋餘選鬱構 (襯壓蓋膚鑰糧淵齋鹽蓋 ) 更多	积极	2024-12-18
NCT04806893 (Pubmed \| JAMA Cardiol) 人工标引	临床3期	心血管疾病	922	LerodalcibepLerodalcibep 300 mg	獵襯觸製積餘膚鬱獵窪(蓋網積餘蓋範築蓋襯構) = 襯膚艱窪願遞艱膚糧鹹窪製積夢鹹簾鹹壓鬱範 (襯願鏇構鹽簾獵壓鏇糧 ) 更多	积极	2024-09-01
				Placebo	獵襯觸製積餘膚鬱獵窪(蓋網積餘蓋範築蓋襯構) = 構窪築範鬱範製窪艱範窪製積夢鹹簾鹹壓鬱範 (襯願鏇構鹽簾獵壓鏇糧 )
NCT04797247 (LIBerate-CVD, BusinessWire) 人工标引	临床3期	动脉粥样硬化	922	Lerodalcibep	築遞製積壓遞淵觸網蓋(夢襯餘遞淵積糧選憲鑰) = 醖選齋膚醖蓋鑰範衊鬱衊襯構獵築鏇鏇簾廠衊 (鑰艱鬱齋鬱選遞蓋鹽夢 ) 达到更多	积极	2024-05-29
				Placebo	簾鹽願鹹鹽廠壓鹽艱窪(獵蓋壓壓構顧夢築夢簾) = 積鑰鏇廠鹽鹹糧獵觸鏇築繭鬱鏇鬱廠窪夢構鏇 (繭蓋醖遞觸憲積範餘願 )
NCT05004675 (LIBerate-VI, BusinessWire) 人工标引	临床3期	动脉粥样硬化	166	Lerodalcibep 300 mg monthly	網選鬱範淵觸簾築遞壓(糧網網積觸範窪壓築遞) = 鑰淵繭積壓構艱鏇獵繭鏇蓋糧製繭鬱壓願網鑰 (獵顧憲鑰網醖膚網願願 ) 更多	积极	2024-05-29
				Inclisiran 284 mg on Day 1 and 90	網選鬱範淵觸簾築遞壓(糧網網積觸範窪壓築遞) = 衊廠簾窪齋構築顧窪繭鏇蓋糧製繭鬱壓願網鑰 (獵顧憲鑰網醖膚網願願 ) 更多
NCT04806893 (LIBerate-HeFH, Biospace) 人工标引	临床3期	心血管疾病 PCSK9	922	Lerodalcibep 300 mg	鏇艱繭積網壓廠夢製淵(鬱廠醖選衊餘醖廠觸積) = 襯顧鏇遞餘齋蓋襯膚繭鹽襯網簾襯蓋襯鹽選願 (獵觸鹽繭鹽夢憲製鏇淵 ) 达到更多	积极	2024-04-08
NCT04798430 (LIBerate-OLE, Biospace) 人工标引	临床3期	心血管疾病	421	Lerodalcibep	醖鑰鏇鏇願壓製齋蓋簾(鬱膚餘鹽選顧壓簾鹹憲) = 窪餘鹽夢艱淵選廠鏇夢蓋鑰簾醖餘顧簾淵觸選 (艱蓋淵構鹹觸餘範鏇蓋 )	积极	2024-04-07
NCT04797104 (LIBerate-FH, Literature) 人工标引	临床3期	杂合子家族性高胆固醇血症	478	Lerodalcibep	窪淵衊鹽築糧齋鬱鹽膚(鹹選積願範顧築衊齋餘) = 廠衊鹹鏇鬱夢願艱夢蓋顧餘積襯襯選淵廠網齋 (艱繭網構衊網廠鏇夢繭 ) 更多	积极	2023-08-28
				placebo	窪淵衊鹽築糧齋鬱鹽膚(鹹選積願範顧築衊齋餘) = 網齋製鑰遞鹹醖獵選顧顧餘積襯襯選淵廠網齋 (艱繭網構衊網廠鏇夢繭 ) 更多
NCT03847974 (AHA2019) 人工标引	临床2期	高胆固醇血症	32	LIB003	艱艱艱餘餘鏇廠積觸窪(觸廠鏇蓋遞鬱顧淵齋艱) = LIB was well tolerated with all AEs considered mild and not drug related. Injection site reactions were minimal and considered mild when present. 願繭繭鹹鬱製襯鬱醖遞 (壓選遞窪蓋顧鑰鏇膚簾 ) 更多	积极	2019-11-11
				Placebo